Neurocrine Biosciences (NBIX) FCF Margin Growth (5y) (2016 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) FCF Margin Growth (5y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,082.00 |
| Mar 31, 2026 | -1,821.00 |
| Dec 31, 2025 | 1,221.00 |
| Sep 30, 2025 | 3,501.00 |
| Jun 30, 2025 | -2,475.00 |
| Mar 31, 2025 | -498.00 |
| Dec 31, 2024 | -133.00 |
| Sep 30, 2024 | -1,836.00 |
| Jun 30, 2024 | -2,355.00 |
| Mar 31, 2024 | 10,722.00 |
| Dec 31, 2023 | -1,091.00 |
| Sep 30, 2023 | 371.00 |
| Jun 30, 2023 | 2,183.00 |
| Mar 31, 2023 | 2,487.00 |
| Dec 31, 2022 | -614.00 |
| Sep 30, 2022 | 4,584.00 |
| Jun 30, 2022 | 80,192.00 |
| Mar 31, 2021 | 23,468.00 |
| Mar 31, 2020 | 10,782.00 |
| Dec 31, 2018 | 155,027.00 |